Evidence map›Paper›PMID 34244232›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2021

Antinociceptive and Discriminative Stimulus Effects of Six Novel Psychoactive Opioid Substances in Male Rats.

Ellen A Walker, Christina Chambers, Matthew G Korber, Srihari R Tella, Cassandra Prioleau, Li Fang

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Antinociceptive Effect and Hyperalgesia of Fentanyl and Its Analogues.International journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ellen A WalkerDepartment of Pharmaceutical Sciences, School of Pharmacy (E.A.W., C.C., M.G.K.) and Center for Substance Abuse Research, Lewis Katz School of Medicine (E.A.W., C.C.), Temple University, Philadelphia, Pennsylvania; and Drug & Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration, Department of Justice, Washington, DC (S.R.T., C.P., L.F.) ellen.walker@temple.edu.
Christina ChambersDepartment of Pharmaceutical Sciences, School of Pharmacy (E.A.W., C.C., M.G.K.) and Center for Substance Abuse Research, Lewis Katz School of Medicine (E.A.W., C.C.), Temple University, Philadelphia, Pennsylvania; and Drug & Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration, Department of Justice, Washington, DC (S.R.T., C.P., L.F.).
Matthew G KorberDepartment of Pharmaceutical Sciences, School of Pharmacy (E.A.W., C.C., M.G.K.) and Center for Substance Abuse Research, Lewis Katz School of Medicine (E.A.W., C.C.), Temple University, Philadelphia, Pennsylvania; and Drug & Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration, Department of Justice, Washington, DC (S.R.T., C.P., L.F.).
Srihari R TellaDepartment of Pharmaceutical Sciences, School of Pharmacy (E.A.W., C.C., M.G.K.) and Center for Substance Abuse Research, Lewis Katz School of Medicine (E.A.W., C.C.), Temple University, Philadelphia, Pennsylvania; and Drug & Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration, Department of Justice, Washington, DC (S.R.T., C.P., L.F.).
Cassandra PrioleauDepartment of Pharmaceutical Sciences, School of Pharmacy (E.A.W., C.C., M.G.K.) and Center for Substance Abuse Research, Lewis Katz School of Medicine (E.A.W., C.C.), Temple University, Philadelphia, Pennsylvania; and Drug & Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration, Department of Justice, Washington, DC (S.R.T., C.P., L.F.).
Li FangDepartment of Pharmaceutical Sciences, School of Pharmacy (E.A.W., C.C., M.G.K.) and Center for Substance Abuse Research, Lewis Katz School of Medicine (E.A.W., C.C.), Temple University, Philadelphia, Pennsylvania; and Drug & Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration, Department of Justice, Washington, DC (S.R.T., C.P., L.F.).
Temple University · USDrug Enforcement Administration · US

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI Munir Gunes Kutlu · 2000 to 2026
$34.6M
NIDA NIH HHS P30 DA013429
6 · The paper itself

Abstract

Compounds with novel or fentanyl-like structures continue to appear on the illicit drug market and have been responsible for fatalities, yet there are limited preclinical pharmacological data available to evaluate the risk of these compounds to public health. The purpose of the present study was to examine acetyl fentanyl, butyryl fentanyl, 3,4-dichloro-

Indexed as

Analgesics, OpioidAnimalsCentral Nervous System AgentsDiscrimination LearningDose-Response Relationship, DrugMalePain MeasurementPsychotropic DrugsRatsRats, Sprague-DawleyReaction TimeAnalgesics, OpioidCentral Nervous System AgentsPsychotropic Drugs

Identifiers

PMID34244232
PMCPMC8626635
OpenAlexW3179876017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.